VoxCell to spotlight 3D bioprinting on Bloomberg Television

VoxCell BioInnovation will appear on Inside Business Today on June 19, 2026, to showcase its human-relevant 3D bioprinted tissue models for drug development. The Chicago biotech says its vascular-first approach could help drugmakers make better decisions earlier, cut late-stage failures and speed therapies to patients. Why it matters: - VoxCell is targeting one of drug development’s biggest problems: most compounds that look safe in animals still fail in human trials. - The company’s tissue models are designed to give pharma and biotech teams more predictive data earlier in preclinical research. - Better early-stage decisions can reduce costly late-stage failures and shorten development timelines. What happened: - VoxCell BioInnovation will be featured on Inside Business Today, hosted by Bill Rancic and Giuliana Rancic. - The segment will air nationally on Bloomberg Television as sponsored programming on June 19, 2026 at 10:30pm CST/8:30pm PST. - Dr. Karolina Valente, VoxCell’s CEO, CSO and co-founder, will appear with Chief Commercial Officer Graham Craig. - The interview will focus on VoxCell’s 3D bioprinted human tissue models and their use in preclinical drug development. The details: - VoxCell was founded in 2020. - Dr. Valente built the company from cancer biology research and from the difficulty of accessing viable human tissue samples. - VoxCell uses proprietary 3D bioprinting technology to create human tissues with micron-scale precision. - The company’s “vascular-first” approach engineers microvascular networks that replicate capillary-level blood vessels. - Those networks are meant to help researchers study drug delivery, drug efficacy and toxic side effects in human tissue. - VoxCell says its models integrate into existing preclinical workflows instead of replacing current methods. - The company works with pharmaceutical companies and contract research organizations. - VoxCell reports a growing team, 12,000 square feet of lab and office space and more than $10 million raised to date. - The company’s website is More information . - Inside Business Today is also available on ReachTV. - The show’s website is the full series site . Between the lines: - The feature lands as drug development faces growing pressure to move away from animal testing and toward human-relevant methods. - VoxCell is positioning its technology as a complement to, not a replacement for, existing screening tools. - That framing could make adoption easier for pharma and CRO partners that want more predictive data without overhauling workflows. - Bill and Giuliana Rancic said VoxCell represents a potential shift in how life-saving therapies are developed and delivered. - Gila Stern, vice president of production at Inside Business Today, said the company is helping solve a major healthcare challenge by bringing better, safer drugs to patients faster. What’s next: - VoxCell’s national TV appearance is set for June 19, 2026. - The company plans to continue scaling its work across the pharmaceutical and biotech industries. - VoxCell is preparing for its next phase of growth as regulatory and scientific momentum build around non-animal testing methods.